Genelux (GNLX) Fireside chat summary

Introduction and agenda

• The session was hosted by a senior biotech analyst and featured the CEO, CFO, and new Chief Medical Officer, focusing on the company's lead oncology asset and clinical progress.

Background and experience of the speaker

• The Chief Medical Officer has 20 years in oncology drug development, with a decade in immuno-oncology, and recently joined the team to advance Olvi-Vec in ovarian cancer and other indications.

Current industry trends

• Oncolytic viruses have evolved since the first approval a decade ago, with new insights into safety, efficacy, and administration routes.

• The field is moving toward combination therapies and systemic delivery to maximize therapeutic potential.